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Background: Overcoming platinum resistance is a major obstacle in the treatment of Epithelial Ovarian Cancer
(EOC). In our previous work Decoy Receptor 3 (DcR3) was found to be related to platinum resistance. The major
objective of this work was to define the cellular interaction of DcR3 with EOC and to explore its effects on platinum
responsiveness.
Methods: We studied cell lines and primary cultures for the expression of and the cells ability to bind DcR3. Cells
were cultured with DcR3 and then exposed to platinum. Cell viability was determined by MTT assay. Finally, the
cells molecular response to DcR3 was studied using real time RT-PCR based differential expression arrays, standard
RT-PCR, and Western blot.
Results: High DcR3 in the peritoneal cavity of women with EOC is associated with significantly shorter time to first
recurrence after platinum based therapy (p= 0.02). None-malignant cells contribute DcR3 in the peritoneal cavity.
The cell lines studied do not secrete DcR3; however they all bind exogenous DcR3 to their surface implying that
they can be effected by DcR3 from other sources. DcR3s protein binding partners are minimally expressed or
negative, however, all cells expressed the DcR3 binding Heparan Sulfate Proteoglycans (HSPGs) Syndecans-2, and
CD44v3. DcR3 binding was inhibited by heparin and heparinase. After DcR3 exposure both SKOV-3 and OVCAR-3
became more resistant to platinum with 15% more cells surviving at high doses. On the contrary CaOV3 became
more sensitive to platinum with 20–25% more cell death. PCR array analysis showed increase expression of BRCA1
mRNA in SKOV-3 and OVCAR-3 and decreased BRCA1 expression in CaOV-3 after exposure to DcR3. This was
confirmed by gene specific real time PCR and Western blot analysis.
Conclusions: Non-malignant cells contribute to the high levels of DcR3 in ovarian cancer. DcR3 binds readily to
EOC cells via HSPGs and alter their responsiveness to platinum chemotherapy. The paradoxical responses seen were
related to the expression pattern of HSPGs available on the cells surface to interact with. Although the mechanism
behind this is not completely known alterations in DNA repair pathways including the expression of BRCA1 appear
to be involved.* Correspondence: jconnor361@gmail.com
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DcR3, also known as TR6, M68, or TNFRSF6B is a sol-
uble protein member of the tumor necrosis factor re-
ceptor family. DcR3 is known to prevent apoptosis via
direct ligand binding of Fas ligand, LIGHT and TL1A,
acting as a decoy for their intended death receptor, Fas,
HVEM/LTβR, and DR3 respectively [1,2]. DcR3 has been
identified in tumor tissue and has been shown to be ele-
vated in the serum of cancer patients were its expression
is often predictive of poor survival [3-7]. We have previ-
ously reported the presence of functional DcR3 in ad-
vanced Epithelial Ovarian Cancer (EOC) ovarian cancer
demonstrating that naturally occurring DcR3 inhibited
Fas-ligand mediated apoptosis. DcR3 was found to be
concentrated in ascites fluid in all cases of advanced
stage disease and higher levels in the peritoneal cavity
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Figure 1 HIGH ascites levels of DcR3 are associated with platinum res
stage IIIC-IVA ovarian cancer were tested for DcR3 by ELISA and the cohort
A. Women with HIGH DcR3 were almost twice as likely to have platinum re
with platinum resistant disease had significantly shorter overall survival (see
shorter time to first recurrence after primary therapy and a trend (D) towarcohort, women with high (greater than the median level)
ascites DcR3 levels were almost twice as likely to mani-
fest platinum resistant disease compared to women
with low levels (62 vs 32% platinum resistant disease
(Figure 1A))[8].
Despite advances in surgical care and improved chemo-
therapeutic agents EOC remains the most lethal of gyne-
cologic malignancies. It is estimated that 23–25,000 US
women are affected annually and unfortunately the major-
ity of them will die of their disease. Aggressive cytoreduc-
tive surgery followed by platinum based chemotherapy is
the mainstay of therapy for these women yet approximately
20% of women treated this way will not respond to this
therapy and are considered platinum refractory. Equally
discouraging, another 10- 20% will be identified with re-
current disease less than 6 months after the completion of
platinum based therapy, bringing the total to 30-40% ofDisease Free Survival by ascites  DcR3 level
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istance in women with EOC. Ascites from forty five women with
divided at the median level into HIGH and LOW DcR3 groups.
sistant disease. B. As would be expected women in this population
ref. 8). C. Women with HIGH DcR3 levels had a significantly
ds shorter overall survival.
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nately once disease has recurred the opportunity for cura-
tive therapy is considered lost. Since platinum is the
cornerstone of ovarian cancer treatment and platinum re-
sistance results in incurable disease an improved under-
standing of the mechanisms of resistance could have major
impact on the management of this disease. To better
understand the association of DcR3 and platinum resist-
ance we explored the role of DcR3 in the response of ovar-
ian cancer cells lines to platinum.
Methods
Antibodies and other reagents
Fas (CD95) and DR3 antibodies were purchased from
eBioscience. Fas ligand antibody was from BD Biosciences
and the BRCA1 antibody (Ab1) was from Calbiochem/
EMD chemicals. LIGHT (CD258), LTβR, HVEM, TL1A,
CD44v3, Syndecan-2 antibodies as well as rhDcR3-Fc,
rhIgG-Fc, and the DcR3 ELISA reagents were obtained
from R&D Systems. The source for heparin and heparinase
1 was Sigma-Aldrich. FITC-conjugated goat anti-human
Fc fragment was purchased from Jackson Immuno-
Research Laboratories. The cancer cell lines SKOV-3,
OVCAR-3, CaOV-3, SW626, and SW480 were obtained
from ATCC. The EOC cell line A2780 and its plati-
num resistant sub-clones were provided by Dr. Thomas
Hamilton, Fox Chase Cancer Institute.
Human subjects and clinical samples
All women taken to the operating room by the gyneco-
logic oncology service at the University of Wisconsin
with a presumed diagnosis of EOC were asked to partici-
pate in this IRB approved protocol. Informed consent
was obtained for the collection of ascites fluid and tumor
tissue at the time of cytoreductive surgery. Ascites was
centrifuged at 1200 rpm for 20 min and the supernatant
fluid frozen at −20°C until assayed by ELISA. The cellu-
lar fraction was frozen in liquid nitrogen in fetal calf
serum with DMSO until thawed for primary cultures.
Demographic information and survival data was taken
from the medical record. Disease free and overall survi-
vals were compared by the method of Kaplan Meier with
the significance of differences determined by Log rank
test. In all analysis significance was set at P ≤ 0.05. A sec-
ond IRB approved protocol was used for the collection
of residual ascites fluid from subjects with no known
clinical history of cancer that were undergoing thera-
peutic paracentesis. This fluid was processed for ELISA
and primary cell culture as stated above for EOC
samples.
Primary cultures
Cell fractions were thawed, washed in sterile PBS and
seeded in 25 cm2 flasks in RPMI media with 10% fetalcalf serum at a cell density of 1X106 cells/flask. For ad-
hesion based tumor enrichment experiments the cells
were allowed to attach at 37°C for one hour then all
none adherent cells were transferred to a new flask and
allowed to attach for 24 h. All cultures were washed and
fresh media added after 24 h. Media samples for DcR3
were then collected at 72 h and frozen at −20°C until
ELISA for DcR3 was done. Cells were analyzed for
EpCAM expression by flow cytometry at the time of
media collection.
Flow cytometry
The expression the protein binding partners of DcR3 and
their native ligands (Fas, FasL, LIGHT, LTβR, HVEM,
DR3, and TL1A) was determined by flow cytometry. The
listed antibodies were incubated with cells for 30 min
at 4°C using manufacturer-recommended concentrations.
Cells were then washed and incubated with 1.5 μg of
streptavidin PE (if necessary) for a further 30 min at 4°C.
After secondary incubation, cells were washed and ana-
lyzed on the cytometer, BD Biosciences FACSCalibur.
All flow experiments were performed with the addition
of propidium iodide to enable the exclusion of dead cells
from the analysis. Flow data analysis was performed with
Treestar’s FloJo software.
To determine the ability of cell lines to bind DcR3
cells were detached using Puck’s EDTA, then divided
into the appropriate tubes and incubated with either
1 μg/200μL of rhDcR3-Fc or rhIgG-Fc for 45 min at 4°C.
Cells were then washed in 1% FBS-PBS and further in-
cubated with 1.5 μg of goat anti-human Fc FITC for
30 min at 4°C. Cells were washed again and fluorescence
signal of the stained cells was detected using a BD Bio-
sciences FACSCalibur. Initial experiments showed no dif-
ference between cells stained with rhIgG-Fc+ anti-human
Fc FITC and anti-Fc FITC alone, so anti-Fc alone was
used as the negative control.
In order to block the rhDcR3-Fc from binding 1 μg of
rhDcR3-Fc or rhIgG-Fc was mixed with 500U of heparin
and incubated for 30 min at room temperature before
adding to the cells for staining as described above.
In experiments requiring the removal of heparin bind-
ing sites prior to incubation with rhDcR3-Fc, cells were
detached as before, then incubated with 20U/mL
heparinase or 0.25% trypsin for 2 h at 37°C with periodic
agitation. Cells were then washed and stained as stated
previously.
Platinum cytotoxicity assays
A single flask each of SKOV-3, OVCAR-3 and CaOV-3
cells were split equally by trypsin EDTA. The media for
one daughter flask from each cell line was supplemented
with rhDcR3-Fc at a concentration of 0.1 μg/ml. The
DcR3 treated cells were then maintained in media with
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untreated control cells (from the same original culture)
for 12 weeks. At this point cells from each of the 6 cell
lines were expanded and frozen for future use. Since we
had theorized that DcR3 would result in increased plat-
inum resistance we elected to treat each cell line with a
range of high dose platinum to test this theory. Cells
were harvested and plated in 24 well plates in triplicate.
After allowing 24 h for cell attachment, media was replaced
and wells were treated in triplicate with cis-platinum at
final concentrations of 2.5-25 μg/ml. After 72 h cell via-
bility was determined by MTT assay (Sigma-Aldrich) and
platinum response was reported as percent of untreated
control wells. ANOVA with Bonferroni’s multiple compari-
son was used to assess for differences based on DcR3 treat-
ment and between platinum doses. These experiments
were repeated four times over a series of passages.Real time RT-PCR array
SKOV-3, CaOV-3 and OVCAR-3 cells were grown for
three months either untreated or continuously treated
with 0.1 μg/ml rhDcR3-Fc. The cells were homogenized
in Trizol at 80-90% confluence and RNA was extracted
according to the manufacturer’s instructions (Sigma, St
Louis). Extracted RNA was further purified using RNeasy
kit (Qiagen) according to the manufacturer’s protocol.
RNA purity was assessed using Nano-drop spectrophoto-
meter, which showed the 260/280 ratio of all the samples
were 2.0 or greater. Purified RNA was reverse tran-
scribed to make cDNA using SABiosciences first strand
cDNA synthesis kit (C-033). The changes in gene expres-
sion of treated cells compared to untreated cells were de-
termined by analyzing the cDNA on the 96 well Cancer
Pathway Finder PCR array from SABiosciences (PAHS-033)
on a Bio-Rad iCycler, using RT2 real time SYBR green
PCR master mix PA-011. Genes of interest were defined
as any gene with at least 1.5 fold change in the same di-
rection in at least two of three replicate samples.Real time PCR for BRCA-1
The untreated and DcR3 treated cells (SKOV-3, CaOV-3
and OVCAR-3) were homogenized in Trizol (Sigma, Cat
No T9424) and RNA was extracted according to the man-
ufacturer’s instructions. The RNA was reverse transcribed
into cDNA using Omniscript RT kit from Qiagen (Cat.
No.205111). The BRCA-1 and S27 were amplified with
the primers obtained from SA Biosciences (Real time
PCR primers for Human BRCA1, Cat No. PPH00322E
and Human S27, cat No PPH17248B) using SsoFast
Evagreen Supermix from BioRad (Cat. No. 172–5201)
on CFX96 Real-Time PCR Detection System. The three
step cycling conditions used were, 95°C for 30s, followed
by 40 cycles of the denaturation at 95°C for 1 s,annealing at 60°C for 5 s. The data was analyzed using
the CFX software manager.
Standard RT-PCR for BRCA-1
The untreated and DcR3 treated cells (SKOV-3, CaOV-3
and OVCAR-3) were homogenized in Trizol and RNA
was extracted according to the manufacturer’s instructions.
The RNA was reverse transcribed into cDNA using
Omniscript RT kit from Qiagen (Cat. No.205111). The
BRCA-1 was amplified with the primers (sense,
5’- TGAGGCATCAGTCTGAAAGTTCTGGA-3’ and anti-
sense, 5’- CTGATGTGCTTTGTTCTGGA-3’) using fast
cycling PCR kit from Qiagen (Cat. No. 203745). The cyc-
ling conditions used were, initial activation at 95°C for
5 min, followed by 30 cycles of the denaturation at 96°C
for 5 s, annealing at 60°C for 5 s and extension at 68°C
for 10s, with final extension at 72°C for 1 min. The PCR
product was run on 2.5% agarose gel at 100 V for 2 h and
bands were visualized using Flourchem8900 ultraviolet
transilluminator. Bands were quantified using Image J
(NIH) normalized to GAPDH.
Western blot analysis for BRCA-1
Ovarian cancer cell lines SKOV-3, CaOV-3 and OVCAR-3
were grown for three months either untreated or treated
with DcR3 as described. When the cells were 80-90%
confluent, the cells were washed with ice cold PBS and
lysed in RIPA lysis buffer containing protease inhibitors.
The cell lysate was briefly sonicated and centrifuged
then the protein concentration was determined using
the BCA method. The protein samples were heat de-
natured (95°C, 5 min) in Laemmli buffer and proteins
(50ug/lane) were separated on 4-15% SDS-PAGE gels,
electro blotted on PVDF membrane and probed with a
mouse monoclonal antibody (1:50) against human BRCA-1
(clone Ab-1). The membrane was incubated in the pri-
mary antibody overnight at 4°C, then washed with PBST
before incubating in HRP conjugated goat anti-mouse
secondary antibody for 1 h at RT. The membrane was
washed again before visualizing the protein with the
super signal west femto maximum sensitivity substrate
(Pierce). The immunoreactive signals were quantified using
Image J (NIH), normalized to β-Actin.
Results
After additional follow-up, our original cohort of women
[8] continue to support a relationship between DcR3
and platinum resistant disease in that women with high
ascites DcR3 have a significantly shorter time to first re-
currence after platinum based primary therapy, 5.5 months
vs. 10 months p= 0.02, (Figure 1C). The high DcR3
group also showed a trend towards worse overall sur-
vival by ten months (p= 0.11, Figure 1D).
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lines including the colon cancer cell lines SW480 and
SW626. Contrary to this none of the ovarian cancer cell
lines we have tested to date have demonstrated detect-
able levels of DcR3 in their media (Figure 2A). Of inter-
est, primary cultures of peritoneal cells from women
with EOC did secrete DcR3 (Figure 2B). Since these cul-
tures are a mix of tumor cells, mesothelial cells, fibro-
blasts and immune cells we performed adhesion based
cell enrichments for tumor cells (EpCAM positive cells)
and found that cells that rapidly adhere to plastic (few
tumor cells) produce more DcR3 than the cells from the
same sample that were allowed 24 h to attach (enriched
for tumor cells, Figure 2C). Flow cytometry for EpCAM
as an indicator of tumor cells in these culture pairs
found that the second cultures were significantly en-
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Figure 2 None-malignant cells contribute to DcR3 in EOC. DcR3 levels
of cells. A. DcR3 is not produced by the EOC cell lines tested as compared
by primary culture of peritoneal cells (mix of cells including immune cells,
ovarian cancer and the level in culture correlates to the levels in the patien
one hour or less (Pt#-1) produce as much or more DcR3 than cells that we
as much or more DcR3 however have 50-95% fewer cancer cells than the
none-malignant ascites produce DcR3 (DcR3 is also present in the ascites f
data not shown). Taken together these results suggest that non-malignant
advanced EOC.produces less DcR3 than the first adhesion culture with
only a fraction the number of tumor cells, (Figure 2D).
Lastly we cultured peritoneal cells from patients without
cancer but who had ascites secondary to chronic liver
disease. As seen in Figure 2E these non-malignant peri-
toneal cells produce DcR3 at levels very similar to the
peritoneal cells from ascites of women with ovarian can-
cer. Taken together these results suggested that cells
other than or in addition to tumor cells are a significant
source of DcR3 in the peritoneal cavity of women with
ovarian cancer. Based on this we theorized that even in
cases were the cancer cells do not produce excessive
DcR3 (like the ovarian cancer cells lines tested here)
they may be influenced by DcR3 produced by other cells
in the tumor micro-environment.
None of the cell lines had evidence of surface bound



































































were determined by ELISA and values compared to media devoid
to the colon cancer cell lines SW626 and SW480. B. DcR3 is produced
stromal cells, mesothelial cells, and tumor cells) from women with
t’s ascites fluid (data not shown). C-D. Cells that adhere to plastic in
re allowed 24 h to adhere (Pt#-2). D. Rapidly adherent cells produce
24 h samples. E. Primary culture of peritoneal cells from patients with
luid at levels similar to the malignant ascites of ovarian cancer,












































































Figure 3 Ovarian cancer cell lines bind DcR3. A. Flow cytometry shows that there is no baseline cell surface DcR3 on the EOC cell lines tested
(upper row) however recombinant human DcR3 (rhDcR3-Fc, R&D Systems) binds to the surface of EOC cell lines (lower row). Incubated with 1 μg
rhDcR3-Fc, SKOV-3 binds the most DcR3 and CaOV-3 binds the least DcR3. B, DcR3 binding, defined as MFI by flow cytometry (solid black bars)
is in direct proportion to the cell lines sensitivity to platinum (grey hatched bars) consistent with the clinical association of DcR3 to platinum
resistant disease (CDDP=Cis-platinum 2.5 μg/ml).
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http://www.biomedcentral.com/1471-2407/12/176all three lines were found to diffusely bind exogenous
DcR3 (rhDcR3-Fc) to their cell surfaces. As shown in
Figure 3A, bottom row, SKOV-3 cells bind more DcR3
than OVCAR-3 cells and CaOV-3 cells bind the least. We
next tested the three cell lines for their sensitivity to
platinum and found that in 2.5 μg/ml of cis-platinum
(CDDP), CaOV3 was the most sensitive line, SKOV3 was
the most resistant, and OVCAR-3 demonstrated an inter-
mediate response to platinum (Figure 3B hatched bars).
The cells’ responses to platinum were found to be in direct
proportion to the individual cell lines’ degree of DcR3
binding by flow cytometry (Figure 3B solid black bars),
i.e. SKOV3 bound the most DcR3 and CaOV3 the least.
To determine the mechanism of binding, we evaluated
the cell lines by flow cytometry for the surface expressionof the cell surface protein ligands of DcR3: LIGHT, Fas-
ligand and TL1A. As seen in Figure 4, although there is a
slight positive shift for LIGHT, overall the three protein
ligands are not present to a degree that would explain
the exogenous DcR3 binding seen in Figure 3A. All of
the cell lines tested are known to express surface Fas
and the flow cytometry confirms this as well as showing
that the cells do not express the other death receptors
(HVEM/LTβR and DR3) known to interact with DcR3s
protein ligands (data not shown).
In addition to its anti-apoptotic properties, DcR3 has
more recently been found to modulate cellular events in-
dependent of its three protein ligands. Based on the pres-
ence of a heparin binding motif in the amino acid structure
of DcR3, many effects of DcR3 have been found to be

















































































Figure 4 Ovarian cancer cell lines do not express high levels of DcR3 protein binding partners. The cell lines studied do not express the
protein ligands for DcR3 (except for low levels of cell surface LIGHT) to account for the binding pattern seen in Figure 3A.
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teoglycans (HSPGs)[10,11]. In cells of the immune sys-
tem the responsible HSPGs are primarily Syndecan-2
and CD44v3 [12,13]. As seen in Figure 5, all three cell lines
expressed both Syndecan-2 and CD44v3. In both SKOV-3
and OVCAR-3 there were higher levels of Syndecan-2
(MFI =100-115) as compared to CD44v3 (MFI = 2). Con-
versely, in CaOV-3 cells there was less Syndecan-2
(MFI = 50) by at least half and 10 fold more CD44v3
(MFI 20.7) than in the other two cell lines. The binding
of DcR3 to all three cell lines was completely inhibited by
the addition of heparin sulfate to DcR3 prior to its incu-
bation with the cells (Figure 6A). DcR3 binding was also
significantly reduced after treatment of the cells with
heparinase to remove the heparan sulfate moieties from
HSPGs or with trypsin to strip the protein backbone of the
HSPGs (Figure 6B). As a flow cytometry control, these
treatments appropriately reduced, trypsin, or had no effect,
heparinase, on the surface expression of the protein adhe-
sion molecule EpCAM (Figure 6C). Taken together, this
indicates that DcR3 interacts with EOC cells via HSPGs.Based on our theory that cancer cells can be effected
by DcR3 even when they do not over produce DcR3 we
chronically cultured each of the 3 EOC cell lines in con-
tinuous DcR3 at 0.1 μg/ml for 12 weeks (approximately
20 passages) to determine if there were any effects on cell
proliferation or response to platinum. All 3 cell lines be-
came more adherent as evident by an increase in the time
needed to harvest the cells in 0.25% trypsin/EDTA solu-
tion (data not shown). There were no significant effects
on cell proliferation seen in response to DcR3 (Figure 7
growth curve insets for each cell line). Since we were
theorizing increased platinum resistance in response to
DcR3, after 12 weeks cells were plated and treated with
high dose cis-platinum (range 2.5- 20 μg/ml) for 72 h.
As seen in Figure 7A-B SKOV3 and OVCAR-3 cells be-
came significantly more resistant to platinum even at the
extremely high doses of 15–20 μg/ml, with a mean of
15% more viable cells after 72 h (p< 0.001 by ANOVA
for both cell lines). This difference became more pro-
found after removal of platinum and continued culture

































MFI 99.9MFI 49.4 MFI 113.6
MFI 2.3MFI 2.2MFI 20.7
Syndecan 2
CD44v3
Figure 5 Ovarian cancer cells express cell surface Heparan Sulfate Proteoglycans known to bind DcR3. Flow cytometry demonstrates the
presence of the known DcR3 binding HSPGs, Syndecan-2 and CD44v3 on the surface of EOC cell lines. Syndecan-2 is the dominant HSPG in
SKOV-3 and OVCAR-3 cells where in CaOV-3 Syndecan-2 expression is half that of the other two cell lines but CD44v3 expression is tenfold
higher than the other lines.
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(no DcR3 treatment) showed continued loss of cells
while the DcR3 treated cultures remain relatively stable
in cell density. Eosin staining of cells demonstrated that
50-60% of these cells were viable. Unexpectedly, the ef-
fects on CaOV-3 were the exact opposite as the cells be-
come more sensitive to platinum with 20-25% more cell
death (Figure 7D) even at the lowest doses tested. These
experiments were repeated a total of 4 times with similar
results each time as seen in the representative photo-
micrographs in Figure 8.
This data would suggest that DcR3 can either increase
resistance to, or enhance the cytotoxic effects of plat-
inum. To determine if there are any molecular/genetic
differences in the effects of DcR3 in each cell line we
performed focused real time reverse transcriptase PCR
based arrays using the SABiosciences’ (Qiagen) Cancer
Pathway Finder system. This 96 well based RT-PCR as-
say was used to compare the differential expression of
86 cancer associated genes between each cell line and
it’s chronically DcR3 treated sub-clone. As seen in
table 1, among the three cell lines 55 genes were found
to be altered (by at least 1.5 fold change up or down in
at least 2 of 3 replicate arrays) after chronic exposure toDcR3. The array data was then analyzed for patterns
of gene expression that fit the paradoxical alterations in
platinum response after DcR3 exposure between SKOV-
3 and OVCAR-3 compared to CaOV3. This resulted in
the identification of the 5 genes in table 2. Of these, the
pattern seen for BRCA1 mRNA was of particular inter-
est given the known association between BRCA1 expres-
sion and response to DNA damaging agents such as
platinum. To further assess this pattern EOC cells and
their chronically DcR3 exposed variants were tested by
standard real time reverse transcriptase PCR and West-
ern Blotting for BRCA1 at the mRNA and protein lev-
els respectively. As seen in Figure 9A-B (A, mean of
triplicate samples and B, examples of individual melt
curves), RT-PCR confirmed the array results in that
BRCA1 mRNA was reduced in CaOV3 cells and in-
creased in SKOV-3 and OVCAR-3 cells after chronic ex-
posure to DcR3 (The same results were seen by standard
reverse transcriptase PCR and densitometry for each
sample, data not shown). Similar changes were seen at
the protein level where BRCA1 was reduced by 31%
in CaOV-3 cells and increased by 25% in SKOV-3









































































Figure 6 DcR3 binding to EOC is heparin sulfate dependent. A. DcR3 binding is completely inhibited by heparin sulfate in all three cell lines.
B. DcR3 binding is also inhibited by the removal of heparan sulfates from HSPGs on the cells surface with heparinase or by removal of complete
HSPGs with their peptide backbone by trypsin. C. The surface adhesion molecule EpCAM was used as a control for heparinase and trypsin
treatments with appropriate responses seen.
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Figure 7 DcR3 modulates response to platinum in ovarian cancer cell lines. A and B, Chronic exposure to DcR3 in culture (12 weeks)
resulted in increased resistance to cis-platinum in SKOV-3 and OVCAR-3 cells with a mean of 15% more viable cells across a wide range of very
high platinum doses, p< 0.001 by ANOVA. C. Photomicrographs demonstrate that DcR3 exposed SKOV-3 cells remain adherent and alive 48 h
after platinum has been removed from the cultures where cell numbers continue to decline after platinum has been removed from the
parent SKOV-3 cell line. DcR3 treated cells were 60% viable at 48 h by eosin stain. D. CaOV-3 cells exposed to DcR3 under identical conditions
demonstrated increased cytotoxicity in response to platinum with> 25% more cell death even at the lower doses, p< 0.001 by ANOVA.
Insets indicate that DcR3 exposure has no significant effects on the growth rate of the cell lines tested.
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The overexpression of DcR3 in human malignancies has
been show to permit and or promote tumor growth viamultiple mechanisms. Many of these have focused on
DcR3 effects on the immune system. DcR3s has been















Figure 8 DcR3 modulates response to platinum in ovarian cancer cell lines. Representative photomicrographs highlight the paradoxical
response to platinum after DcR3 exposure.
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http://www.biomedcentral.com/1471-2407/12/176as well as to alter local chemokine production to result
in a Th2 inflammatory local environment [14-16]. DcR3
also demonstrates diverse effects on cells of monocyte/
macrophage lineage were it has been shown to increase
monocyte adhesion [13,17], skew macrophage to an M2
tumor associated phenotype, negatively alter their
antigen presenting function, and to directly result in





SYK, ANGPT1, IL8, PDGFB,




DOWN ATM, CDKN2A (P16), E2F1,
APAF1, BCL2, FOS, ITGB5,
ANGPT2, COL18A1, FGFR2,
INF-A, INF-B, TGFBR1, TNF,
VEGFA, MMP2, MMP9provides data to support a novel pro-tumor effect of
DcR3 via its association with platinum resistant disease.
Although DcR3 has been reported to be elevated in both
the blood and ascites of women with ovarian cancer the
functional or prognostic significance of this is not clear
[8,23]. Our prior data indicated an association with plat-
inum refractory disease, a finding further supported by































Table 2 Genes with patterns of altered expression in
response to chronic DcR3 that correspond to the
alterations in response to platinum as seen in Figure 6
GENE SKOV3 OVCAR3 CAOV3
BRCA1 UP UP DOWN
E2F1 DOWN DOWN UP
GZMA UP UP N/A
Fas UP UP N/A
COL18A1 DOWN DOWN UP
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with high peritoneal DcR3 levels confirming our prior
association with platinum resistance.
In many cancers studied (colon, pancreas, hepatocellu-
lar) DcR3 has clearly been shown to be over produced
by cancer cells and there are representative DcR3 pro-
ducing cancer cell lines. We have seen high levels of
DcR3 in the peritoneal cavity of women with advanced
EOC yet have not found an EOC cell line that secretes
DcR3 into its culture media. This led us to evaluate
whether none-malignant cells in the peritoneal cavity
from EOC cases were responsible for the DcR3 pro-
duction in these cancers. This theory is supported by a
significant body of evidence for abnormal DcR3 pro-
duction from many none-malignant cell types including
fibroblasts, synovial cells, inflamed GI mucosa, and vari-
ous cells of the immune system. Although the data
presented here does not exclude tumor cells as a partial
source of peritoneal DcR3 in EOC we have demon-
strated significant production of DcR3 by none-malignant
(EpCAM negative) cells and this finding was the ration-
ale for the cell line experiments and interesting paradox-
ical results described here. Our data shows that DcR3
can either increase resistance or enhance the cytotoxic
effects of platinum and we theorize that the effects on
platinum response may depend on which HSPGs are ex-
pressed on the cell surface. In SKOV-3 and OVCAR-3
cells the predominant HSPG is Syndecan-2. In these
cells DcR3 exposure results in increased resistance to plat-
inum. Conversely CaOV-3 cells express CD44v3 at more
than 10 fold the level in the other cell lines and become
more sensitive to lower doses of platinum after exposure
to DcR3. In our original series of patient samples, DcR3
was identified in ascites fluid of all women with advanced
EOC with a wide range of concentrations, 70–14,000 pg/ml
and women with high DcR3 were twice as likely to
manifest platinum resistant disease. Despite this statisti-
cally significant finding there were women with high
levels who were platinum sensitive and women with lower
levels who were platinum resistant (see Figure 1A). The
cell line data presented here may offer an explanation
for this in that cell lines with Syndecan predominant
HSPG pattern (or perhaps, as described for survival inother cancers, cells that have lost CD44v3 expression)
become more platinum resistant when chronically ex-
posed to DcR3 while the cell line with CD44v3 as a
more dominant HSPG become more platinum sensitive.
Thus the effect of even very high levels of local DcR3 in
terms of platinum responsiveness may depend on the
cancer cells pattern of DcR3 binding partners and not
just the presence of DcR3. We are currently collecting
samples and clinical data on a larger group of women to
verify this theory.
Neither Syndecan-2 nor CD44v3 have been extensively
studied in EOC, however data from other tumor types is
consistent with our preliminary findings and hypothesis.
CD44 is a transmembrane molecule that functions as
both an adhesion molecule and in some cases as a cell
signaling receptor. The full molecule, often called CD44
standard (CD44S) has been found to be expressed or
over expressed in a variety of cancers including EOC. In
addition to CD44S, malignant cells can express a num-
ber of variant CD44 molecules as the result of post
translational modifications. CD44v3 is one of these var-
iants but is unique in that it is decorated with Heparan
Sulfates, (i.e. it is a HSPG), as noted above. The role of
CD44v3 in cancer is tumor type dependent; however in
many malignancies studied, its expression is associated
with a better prognosis compared to tumors that lack
CD44v3 expression. In melanoma, CD44v3 expression is
associated with other key prognostic factors resulting in
a 75% 5 year survival in CD44v3 positive tumors vs. 45%
in negative cases, p= 0.0072 [24]. Similarly, CD44v3 is
present in the majority of benign uterine fibroids but is
uniformly absent in uterine sarcomas [25]. In adenocar-
cinoma of the lung, CD44v3 is present in non-invasive
lesions but is not expressed in the presence of frank in-
vasion. In this tumor type, recurrence was more com-
mon and disease free survival was shorter in CD44v3
negative lesions in both univariate and multivariate ana-
lyses (p= 0.01 and 0.03 respectively) [26]. In squamous
lesions of the uterine cervix CD44v3 is reduced in inva-
sive vs. pre-invasive lesions; however in squamous vulvar
lesions CD44v3 is increased in invasive lesions with a
more aggressive natural history. Similarly in colon can-
cer CD44v3 expression is seen in over 50% of cases and
was associated with a poor prognosis [27,28]. CD44v3
expression is variable and was not found to be related to
prognosis in either direction in thyroid, gastric, gall blad-
der, or invasive transitional cell bladder cancers[29].
In EOC, CD44v3 has been seen in both tumors of low
malignant potential and invasive disease. In invasive dis-
ease, lack of CD44v3 was associated with a poor progno-
sis. Lack of CD44v3 was more common in higher stage
lesions and was associate with poor survival in both uni-
variate (p= 0.027) and multivariate analysis (p= 0.026)
independent of stage and lymph node status. These
CaOV control




































Figure 9 BRCA1 mRNA and protein expression are modulated by DcR3. Real time reverse transcriptase PCR (A. means of triplicate samples
by RT-PCR and B. examples of individual melt curves) and Western Blot (C) for BRCA1 demonstrate that the differential changes in BRCA1
expression between SKOV-3/OVCAR-3 and CaOV-3 cells exposed to DcR3 are in line with the changes seen in platinum responsiveness from
the same DcR3 treated cultures.
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pression is associated with a better response to platinum
especially in the presence of high levels of DcR3[30].
Syndecan-2 is a HSPG that is known to function as a
co-receptor for key growth factors including FGF-2, VEGF,
EphB2, and TGFβ and to facilitate interactions between the
extracellular matrix (ECM) and cell membrane/cell cyto-
skeletal functions such as vesicle transport. synaptic for-
mation, and cell locomotion via filopodia formation[31].
Syndecan-2 is thought to be an important factor in nor-
mal development and its abnormal expression has been
associated with colon and lung cancers, where it is found
to facilitate metastasis by increasing motility and pro-
moting angiogenesis [32,33]. Little is known about the
functions of Syndecan-2 in EOC, although it is known to
be expressed in both tumor associated stroma and on the
surface of epithelial cells [34,35] . On the surface of cancer
cells Syndecan-2 has been found to interact with other key
cell surface signaling molecules including caveolin-2,
RACK1, p120, and STAT3, all of which influence the ac-
tivation of the oncogenes ras and Src, which in turn are
key factors in the pathogenesis of EOC[36-40].
Although our data does not exclude the involvement
of multiple mechanisms it suggests that DcR3 may alter
response to platinum at least in part by regulating the
expression of BRCA1. Our understanding of the func-
tions of BRCA1 in ovarian cancer is evolving and com-
plicated however there is consistent evidence of a role in
response to DNA damaging agents such as platinum
[41-43]. In 1998 Husain demonstrated that BRCA1 mRNA
was upregulated and the protein overexpressed in plat-
inum resistant sub-clones of both MCF-7 and SKOV-3
cells. In addition to platinum resistance BRCA1 overex-
pression was associated with improved DNA repair (an
area we have not yet explored in our chronically exposed
DcR3 system). In this study, transfection with BRCA1
anti-sense constructs was shown to reverse both pro-
cesses [44]. Similarly, Horiuchi verified that suppression
of BRCA1 lead to increased apoptosis in response to
platinum and that this was associated with enhanced
p53 and p21 function [45]. Our data are consistent with
these findings in that DcR3 exposure results in increased
BRCA1 expression in the two lines that became more
resistant and reduced BRCA1 in the CaOV3 cells as they
became more sensitive to platinum after chronic DcR3
exposure. In addition our array data support this by sim-
ilar expression alterations of both p53 and p21 in
OVCAR-3 cells and an increase an in p21 expression in
CaOV3 cells (table 1). Further study into the potential role
of BRCA1 in this process will require investigation into
other possible mechanisms of BRCA1 regulation including
assessment of its phosphorylation status and the physical
location of the BRCA1 protein and or its protein complex
partners in these cells.Conclusions
Based on the data presented we conclude that non-
malignant cells contribute to the high levels of DcR3
found in the peritoneal cavity of women with ovarian
cancer. DcR3 binds readily to EOC cells via HSPGs and
alter their responsiveness to platinum chemotherapy.
Two of three cell lines tested became more resistant to
platinum were the third showed increased sensitivity to
platinum. This paradoxical response appears to be related
to expression pattern of HSPGs available on the cells sur-
face to interact with. Although the mechanism behind
this is not completely known alterations in DNA repair
pathways including the expression of BRCA1 appear to
be involved.
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